A5076550697- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Cytokine Signaling Pathways and Interactions
- Neuroendocrine Tumor Research Advances
- Single-cell and spatial transcriptomics
- Pancreatic and Hepatic Oncology Research
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Myasthenia Gravis and Thymoma
- Occupational and environmental lung diseases
- Asthma and respiratory diseases
- Respiratory and Cough-Related Research
- Inflammatory Biomarkers in Disease Prognosis
- Peptidase Inhibition and Analysis
- Neuroblastoma Research and Treatments
- Pleural and Pulmonary Diseases
- Gastric Cancer Management and Outcomes
- CAR-T cell therapy research
- Cancer therapeutics and mechanisms
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Esophageal Cancer Research and Treatment
- Radiomics and Machine Learning in Medical Imaging
Saitama Medical University
2017-2025
National Disaster Medical Center
2013-2024
National Hospital Organization
2013-2024
Saitama Prefecture
2024
Hidaka Hospital
2023
Taiho Pharmaceutical (Japan)
2022
Eli Lilly (Japan)
2022
Ono Pharmaceutical (Japan)
2022
Saitama University
2020-2021
Saitama International Medical Center
2017-2020
It is unclear whether the chemotherapy response improves after exposure to immunotherapy. Antiangiogenic agents have been shown stimulate immune system and cause synergistic effects that tumor shrinkage. We conducted a retrospective study evaluate improvement of efficacy ramucirumab plus docetaxel failure nivolumab as PD-1 inhibitor.From February 2016 December 2017, 152 patients with non-small cell lung cancer (NSCLC) administered in our institution were identified. reviewed records 20 NSCLC...
It remains unclear whether the accumulation of 2-deoxy-2-[18F]fluoro-d-glucose (18F-FDG) before initiation anti-programmed death-1 (PD-1) antibody can predict outcome after its treatment. The aim this study is to retrospectively examine prognostic significance 18F-FDG uptake as a predictive marker anti-PD-1 antibody. Eighty-five patients with previously treated non-small cell lung cancer (NSCLC) who underwent 18F-FDG-positron emission tomography (PET) just administration nivolumab or...
Tumor-infiltrating lymphocytes (TILs) in the tumor and stroma are expected to accurately predict efficacy of programmed death-1 (PD-1) blockade therapy. However, little is known about prognostic significance TILs first-line PD-1 We assessed patients with advanced or metastatic non-small cell lung cancer (NSCLC) treated pembrolizumab palliative setting.Multiplex immunohistochemistry staining (CD4, CD8, Foxp3, PD-1) immunohistochemical CK PD-L1 was performed specimens 107 NSCLC correlated...
Background It remains unclear why radiation clinically provides a synergistic effect when combined with immune checkpoint inhibitors such as nivolumab. The purpose of our study was to retrospectively evaluate whether the therapeutic efficacy nivolumab is improved result history radiotherapy (RT) in patients previously treated advanced non‐small cell lung cancer (NSCLC). Methods From February 2016 December 2017, 124 consecutive were administered for pretreated NSCLC. divided into RT and...
Background Chemoradiotherapy followed by durvalumab is the standard treatment for patients with local advanced non‐small cell lung cancer (NSCLC). There a real‐world data about management of adverse events, such as pneumonitis, according to different institutions. Here, we present experience regarding events after initiation daily practice. Methods From July 2018 August 2019, 41 locally NSCLC, who underwent chemoradiotherapy durvalumab, were retrospectively analyzed in study using our...
Abstract CD4+ T-cell immunity helps clonal proliferation, migration, and cancer cell killing activity of CD8+ T cells is essential in antitumor immune responses. To identify clusters responsible for immunity, we simultaneously analyzed the naïve-effector state, Th polarization, receptor clonotype based on single-cell RNA-sequencing data. Unsupervised clustering analysis uncovered presence a new metacluster CD62Llow subpopulation, which contained multicellular clonotypes associated with...
Abstract Background There are no established biomarkers for predicting the efficacy of first‐line pembrolizumab monotherapy in patients with high programmed death‐ligand 1 (PD‐L1) expression. In this study, we investigated whether Glasgow prognostic score (GPS), neutrophil‐to‐lymphocyte ratio (NLR), and body mass index (BMI) can be used to evaluate effect advanced non‐small cell lung cancer (NSCLC) who express levels PD‐L1. Methods We reviewed data from 142 PD‐L1 expression underwent NSCLC...
The aim of this study was to assess the effectiveness and tolerability atezolizumab plus carboplatin etoposide combination chemotherapy in elderly patients with extensive-disease (ED) small-cell lung cancer (SCLC).This retrospective evaluated 65 SCLC who received atezolizumab, carboplatin, for ED-SCLC nine institutions between August 2019 September 2020. Clinical efficacy, assessed according response rate survival, toxicity were compared (n = 36 patients; median age: 74 years [range: 70-89...
Amrubicin is recognized as a second-line treatment for refractory small-cell lung cancer (SCLC) and administered immediately after chemotherapy; however, it has not been evaluated in patients with recurrent SCLC following chemoradiotherapy (CRT). This study aimed to examine the activity safety of amrubicin monotherapy relapsed previously treated CRT. retrospective who had CRT, followed by between April 2007 June 2021. The clinical efficacy toxicity were assessed. Overall, 30 (20 men 10...
<p>Supplementary Figure S4. OS according to number of whole irAEs Abbreviations: CI, confidence interval; HR, hazard ratio; irAE, immune-related adverse event; NE, not evaluable; NR, reached; OS, overall survival</p>
<p>Supplementary Figure S1. PFS according to the grade of irAE (A) 4 weeks landmark (B) 8 One event with undetermined was excluded from analysis. Abbreviations: CI, confidence interval; HR, hazard ratio; irAE, immune-related adverse event; PFS, progression-free survival</p>
<p>Supplementary Figure S2. PFS of irAE skin or endocrine disorders (A) according to the onset (B) grade One event with undetermined was excluded from analysis grade. Abbreviations: CI, confidence interval; HR, hazard ratio; irAE, immune-related adverse event; PFS, progression-free survival </p>
<p>Supplementary Figure S3. PFS of irAE other than skin or endocrine disorders (A) according to the onset (B) grade One event with undetermined was excluded from analysis grade. Abbreviations: CI, confidence interval; HR, hazard ratio; irAE, immune-related adverse event; PFS, progression-free survival</p>
ABSTRACT Background The combination of nivolumab and ipilimumab, which act on different immune checkpoint molecules, is a promising first‐line treatment strategy for advanced nonsmall cell lung cancer (NSCLC). However, real‐world clinical data this regimen, particularly regarding the relationship between adverse events (AEs) efficacy, are inadequate. Methods This retrospective study was conducted patients with or recurrent NSCLC treated using ipilimumab as treatment. We extracted consecutive...
The aim of our study was to retrospectively assess the incidence interstitial lung disease (ILD) related EGFR-tyrosine kinase inhibitor (TKI) treatment immediately before and/or after administration a PD-1 antibody.We analyzed data 26 patients who underwent with EGFR-TKIs an anti-PD-1 antibody.Four out developed ILD during EGFR-TKI treatment: three osimertinib after, and one afatinib antibody. Three 12 therapy antibody experienced osimertinib-induced ILD. not observed in five administered...
Abstract There is a lack of markers for predicting favorable outcomes after pembrolizumab therapy in patients with non-small cell lung cancer (NSCLC) programmed death ligand-1 (PD-L1) expression ≥ 50%. This retrospective study examined the prognostic significance 2-deoxy-2-[18F] fluoro- d -glucose ( 18 F-FDG) uptake as predictive marker first-line pembrolizumab. Forty-eight previously untreated NSCLC and PD-L1 levels 50% who underwent F-FDG-positron emission tomography (PET) just before...